IN2014DN07920A - - Google Patents

Info

Publication number
IN2014DN07920A
IN2014DN07920A IN7920DEN2014A IN2014DN07920A IN 2014DN07920 A IN2014DN07920 A IN 2014DN07920A IN 7920DEN2014 A IN7920DEN2014 A IN 7920DEN2014A IN 2014DN07920 A IN2014DN07920 A IN 2014DN07920A
Authority
IN
India
Prior art keywords
cystathionine
cbs
synthase
purification
prepared therefrom
Prior art date
Application number
Inventor
Richard G Carrillo
Jan P Kraus
Thomas Majtan
David Naveh
Original Assignee
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado filed Critical Univ Colorado
Publication of IN2014DN07920A publication Critical patent/IN2014DN07920A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin, biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides chromatographic methods for the purification of a cystathionine ß Synthase (CBS) protein particularly truncated variants thereof and compositions and pharmaceutical compositions prepared therefrom.
IN7920DEN2014 2012-03-26 2013-03-25 IN2014DN07920A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Publications (1)

Publication Number Publication Date
IN2014DN07920A true IN2014DN07920A (en) 2015-05-01

Family

ID=49212017

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7920DEN2014 IN2014DN07920A (en) 2012-03-26 2013-03-25

Country Status (11)

Country Link
US (4) US9243239B2 (en)
EP (3) EP2831229B8 (en)
JP (3) JP6146934B2 (en)
CN (1) CN104540940B (en)
AU (1) AU2013240003B2 (en)
BR (1) BR112014023570B1 (en)
CA (1) CA2867719C (en)
HK (1) HK1246350B (en)
IL (2) IL234635B (en)
IN (1) IN2014DN07920A (en)
WO (1) WO2013148580A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) * 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
EP3998067A1 (en) * 2015-11-09 2022-05-18 The Regents of the University of Colorado, a body corporate Compositions and methods for treatment of homocystinuria
WO2018195006A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
US20220315965A1 (en) * 2019-06-25 2022-10-06 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
AU2020302079A1 (en) * 2019-06-26 2022-02-17 The Regents Of The University Of Colorado, A Body Corporate Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
AU2003251550A1 (en) 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (en) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 Cystathionine-game-synase specific expression sequence label of tea tree and its biologic chip
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
US8709407B2 (en) 2010-02-04 2014-04-29 Aemase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Also Published As

Publication number Publication date
EP2831229B8 (en) 2018-10-17
EP3569706A1 (en) 2019-11-20
JP2020000259A (en) 2020-01-09
CN104540940B (en) 2018-03-06
JP6839595B2 (en) 2021-03-10
JP2015512639A (en) 2015-04-30
JP6952361B2 (en) 2021-10-20
BR112014023570A2 (en) 2021-06-01
US9243239B2 (en) 2016-01-26
BR112014023570B1 (en) 2022-03-15
AU2013240003A1 (en) 2014-10-02
CA2867719C (en) 2020-08-11
IL263162A (en) 2018-12-31
EP2831229A1 (en) 2015-02-04
IL263162B (en) 2019-11-28
EP3263701A1 (en) 2018-01-03
US20190055537A1 (en) 2019-02-21
IL234635B (en) 2018-12-31
AU2013240003B2 (en) 2018-04-19
EP2831229B1 (en) 2017-10-18
US20160177287A1 (en) 2016-06-23
US20200131497A1 (en) 2020-04-30
EP3263701B1 (en) 2019-06-19
WO2013148580A1 (en) 2013-10-03
JP2017121255A (en) 2017-07-13
JP6146934B2 (en) 2017-06-21
US20130251700A1 (en) 2013-09-26
CN104540940A (en) 2015-04-22
CA2867719A1 (en) 2013-10-03
US10160962B2 (en) 2018-12-25
US10941392B2 (en) 2021-03-09
HK1246350B (en) 2020-05-15

Similar Documents

Publication Publication Date Title
AU2016204248A1 (en) Boron-Containing Molecules
IN2014DN07920A (en)
IN2014DN08481A (en)
IN2015DN00127A (en)
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
EP2742126A4 (en) Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside
GEP20196964B (en) Pest control composition including novel iminopyridine derivative
MY168300A (en) Pharmaceutical Composition for Inhalation
EP2872151A4 (en) Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases
AU2013337247A8 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
HRP20190050T1 (en) Pharmaceutical compositions for combination therapy
SG11201405578TA (en) Pharmaceutical composition containing peptide
EP3022291A4 (en) Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
IN2014DN08412A (en)
WO2014068586A3 (en) Solid oral compositions of tolvaptan
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
MX2015006337A (en) Methods and compositions for treating neurodegenerative diseases.
IN2015DN03132A (en)
MX2015003034A (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same.
IN2014DN07103A (en)
MY165088A (en) Pharmaceutical compositions comprising alisporivir
AP3814A (en) Nasal compositions of vitamin b12
IN2013MU03317A (en)
WO2014122671A3 (en) Solid oral compositions of saxagliptin